| scholarly article | Q13442814 |
| P50 | author | Farhad Ravandi | Q40614280 |
| Jean-Pierre J Issa | Q55459879 | ||
| Jorge Eduardo Cortes | Q60320900 | ||
| Hagop Kantarjian | Q60394812 | ||
| Susan O'Brien | Q66370727 | ||
| Guillermo Garcia-Manero | Q66385413 | ||
| Xuelin Huang | Q87045391 | ||
| Carlos B Bueso-Ramos | Q90223571 | ||
| Jianqin Shan | Q114427924 | ||
| Jan Davisson | Q114427941 | ||
| P2860 | cites work | Proposals for the classification of the myelodysplastic syndromes | Q28275931 |
| Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study | Q28301602 | ||
| International scoring system for evaluating prognosis in myelodysplastic syndromes | Q28305247 | ||
| Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. | Q34128471 | ||
| A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome | Q34308142 | ||
| Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia | Q34553286 | ||
| Novel therapies for myelodysplastic syndromes | Q35829958 | ||
| Bayesian clinical trials | Q36399554 | ||
| Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia | Q40543180 | ||
| Report of an international working group to standardize response criteria for myelodysplastic syndromes. | Q40737646 | ||
| Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia | Q44548405 | ||
| World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. | Q46038765 | ||
| Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome | Q46910751 | ||
| Contribution of β-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS) | Q47924458 | ||
| Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia | Q58865927 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| myelodysplastic syndrome | Q954625 | ||
| chemotherapy | Q974135 | ||
| P304 | page(s) | 1133-1137 | |
| P577 | publication date | 2007-03-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience | |
| P478 | volume | 109 |
| Q37601778 | 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis |
| Q33769335 | A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome |
| Q33939624 | A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML. |
| Q40228044 | A preliminary study on the outcome of lower-risk myelodysplastic syndrome by low-dose decitabine |
| Q24622700 | An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes |
| Q85213650 | Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome |
| Q37277994 | Changing the treatment paradigm in myelodysplastic syndromes |
| Q34686726 | Clofarabine: past, present, and future |
| Q37973280 | Combination strategies in myelodysplastic syndromes. |
| Q46060620 | CpG island methylation patterns in chronic lymphocytic leukemia |
| Q58110507 | Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia |
| Q37771015 | Current and future management options for myelodysplastic syndromes |
| Q48587178 | Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities |
| Q38979940 | DNA Hypomethylating Drugs in Cancer Therapy |
| Q38233492 | Deacetylase inhibitors for the treatment of myelodysplastic syndromes |
| Q36911488 | Decitabine and its role in the treatment of hematopoietic malignancies |
| Q37493954 | Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors |
| Q34088403 | Decitabine in the treatment of myelodysplastic syndromes. |
| Q37742267 | Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone |
| Q34847863 | Demethylating agents in myeloid malignancies |
| Q35039868 | Derivation and validation of the SEER-Medicare myelodysplastic syndromes risk score (SMMRS). |
| Q46047561 | Durable clinical and cytogenetic remission in an elderly patient with relapsed acute myeloid leukemia treated with low-dose lenalidomide |
| Q36001930 | Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies |
| Q38185555 | Epigenetic alterations in osteosarcoma: promising targets |
| Q27694612 | Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response |
| Q37850456 | Epigenetic regulation in myelodysplastic syndromes: implications for therapy |
| Q37184917 | Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias |
| Q37964702 | Epigenetic-based therapies in cancer: progress to date |
| Q38012175 | Epigenetics of estrogen receptor-negative primary breast cancer |
| Q35183982 | Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. |
| Q34768789 | Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies |
| Q28283836 | Feasibility of therapy with hypomethylating agents in patients with renal insufficiency |
| Q90734746 | Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results |
| Q35202854 | How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes |
| Q34667051 | Hypomethylating agents and other novel strategies in myelodysplastic syndromes |
| Q36545064 | Hypomethylating therapy in an aggressive stroma-rich model of pancreatic carcinoma. |
| Q80855046 | Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia |
| Q58706592 | Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: A systematic review and meta-analysis |
| Q36055095 | Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome |
| Q37108489 | Management of myelodysplastic syndromes: 2008 update. |
| Q39172636 | Methylation of promoters of microRNAs and their host genes in myelodysplastic syndromes. |
| Q55021852 | MiR-142-3p is downregulated in aggressive p53 mutant mouse models of pancreatic ductal adenocarcinoma by hypermethylation of its locus. |
| Q36203084 | Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome |
| Q26801573 | Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise? |
| Q26749870 | Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy |
| Q87476851 | Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes |
| Q24323093 | Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine |
| Q55969986 | Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q98471223 | New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP |
| Q54979651 | Outcome of patient with high-risk chronic myelomonocytic leukemia, treated with decitabine prior to transformation to acute myeloid leukemia: A case report. |
| Q42124715 | Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy |
| Q37866296 | Pharmacokinetic evaluation of decitabine for the treatment of leukemia |
| Q38470137 | Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast |
| Q36140902 | Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients |
| Q33380307 | Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System |
| Q34749123 | RUNX3 gene promoter demethylation by 5-Aza-CdR induces apoptosis in breast cancer MCF-7 cell line |
| Q37382559 | Recent progress and clinical importance on pharmacogenetics in cancer therapy. |
| Q39527812 | Response to pretransplant hypomethylating agents influences the outcome of allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndromes |
| Q35058556 | Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia |
| Q33995598 | Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine |
| Q33392293 | Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes |
| Q37320354 | Targeting DNA methylation |
| Q36138278 | The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients |
| Q40092610 | The efficacy and safety of the patients of myelodysplastic syndromes-refractory anemia with excess blasts treated with decitabine alone or CAG/HAG regimen |
| Q37404489 | The evolution of hematopoietic SCT in myelodysplastic syndrome |
| Q36280941 | The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes |
| Q36833557 | The myelodysplastic syndrome as a prototypical epigenetic disease |
| Q36612553 | The revolution of myelodysplastic syndromes |
| Q37271941 | Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years |
| Q38235662 | Update on the pharmacotherapy for myelodysplastic syndromes. |
| Q64059660 | mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy |
| Q43249171 | p53 and DNA methylation suppress the TRAIN to cell death |
| Q36848202 | p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies |
Search more.